Home Newsfeeds Leidos Holdings Awarded Low Altitude Nuclear Explosions Prototype Development Contract From Defense Threat Reduction Agency For $40,626,472.00

Leidos Holdings Awarded Low Altitude Nuclear Explosions Prototype Development Contract From Defense Threat Reduction Agency For $40,626,472.00

https://sam.gov/opp/b52c36c1bc4f4733ad4800e59bb4923e/view

byBenzinga Newsdesk

December 8, 2022

1 minute read

https://sam.gov/opp/b52c36c1bc4f4733ad4800e59bb4923e/view

News

Instil Bio Partners with Cell Therapy Leader for ITIL-306 Program, Eyeing Breakthrough in Lung Cancer Treatment

By Benzinga Newsdesk

January 16, 9:05 AM

Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of

TIL

Double Good News For AstraZeneca’s Breast Cancer Drugs

By Vandana Singh

April 29, 9:25 AM

Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer.

AZN

Nasdaq Jumps 100 Points; Prestige Wealth Shares Spike Higher

By Lisa Levin

July 7, 2:30 PM

U.S. stocks turned higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Friday. The Dow traded up 0.09% to 33,953.96 while the NASDAQ rose 0.73% to 13,779. The S&P 500, also rose, gaining, 0.45% to 4,431.26.

EDTX

News

NextCure’s Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

By Benzinga Newsdesk

October 17, 8:09 AM

NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today

NXTC

Leidos Holdings Awarded Low Altitude Nuclear Explosions Prototype Development Contract From Defense Threat Reduction Agency For $40,626,472.00

Related Posts

Instil Bio Partners with Cell Therapy Leader for ITIL-306 Program, Eyeing Breakthrough in Lung Cancer Treatment

Double Good News For AstraZeneca’s Breast Cancer Drugs

Nasdaq Jumps 100 Points; Prestige Wealth Shares Spike Higher

NextCure’s Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)